Navigation Links
Treating Epilepsy - The Next Big Thing
Date:6/30/2017

HIGH POINT, N.C., June 29, 2017 /PRNewswire/ -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug delivery innovations for developing improved novel formulations and alternative dosage forms of existing biologically active molecule.

Subveta oral spray for transmucosal delivery is based on our waterless self-nano emulsifying formula, which is designed to prevent precipitation of the active ingredient after contact with saliva. We believe the spray will provide fast onset of action and is designed to optimize drug absorption through the oral mucosa.
Subveta oral spray for transmucosal delivery is based on our waterless self-nano emulsifying formula, which is designed to prevent precipitation of the active ingredient after contact with saliva. We believe the spray will provide fast onset of action and is designed to optimize drug absorption through the oral mucosa.
Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.
Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.

Axium's pharmaceutical products are developed using highly effective technologies and demonstrated usefulness in the improvement of bioavailability and biological action of incorporated molecules. The company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Axium is working closely with clinicians, patient advocate groups, and universities worldwide to identify existing health issues where Axium's approach will be most beneficial for patient care.

Axium is patent pending not only on the use of Truveta (Lorazepam) administered intranasally, but also a new intranasal administration product that is highly accurate, reproducible and convenient for delivery of one or more predetermined unit doses of Lorazepam in the form of a nasal spray delivery system.

The objective is to produce the relatively rapid onset of a therapeutic effect and the moderate duration of therapeutic activity, with minimal side effects and improved bio-availability.

Furthermore, the system's delivery method is designed to be safe and easy, producing minimal physical discomfort and anxiety to the patient.

The medication is delivered through a small, inexpensive, manually operated and disposable device, and will be prepared under aseptic conditions; no significant residue is left in the delivery device following administration.

The FDA has accepted an orphan designation request for the intranasal lorazepam, (Truveta) administered intranasally in the Treatment of Lennox-Gastaut syndrome using the formulation that Axium is developing.

Orphan drug designation will provide the following benefits, protocol assistance offered by FDA, tax credits of 50 percent of the clinical drug testing cost awarded upon approval, waiver of NDA/BLA application, waiver of NDA/BLA application fee this is a $2.2 million value and, and the designation would give Axium a seven-year market exclusivity for the sale of Truveta, among many other advantages.

Axium plans to soon be publicly traded. Keep checking the website for updates. www.axium-pharma.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Related Images

image1.jpg

image2.jpg

Related Links

AXIUM PHARMACEUTICALS INC.

Technology / Pipeline

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/treating-epilepsy---the-next-big-thing-300482173.html


'/>"/>
SOURCE Axium Pharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AXONs Tau Vaccine Offers Potential for Treating Frontotemporal Dementia Patients
2. Research on Treating Sleep Apnea with Adaptive Servo-ventilation Published in the Journal of the American College of Cardiology (JACC)
3. Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
4. Entest BioMedical Inc.s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
5. RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4
6. Geisinger study finds opioids not helpful in treating chronic pain
7. National Safety Council Applauds Centers for Disease Control and Prevention for releasing a prescribing guideline for treating chronic pain
8. Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
9. Boston Scientific and Accenture Develop Data-Driven Digital Health Solution to Help Improve Patient Outcomes and Reduce Cost of Treating Chronic Cardiovascular Conditions
10. Dramatic Turn in Story of Invalidated 813 Patent For Treating Binge Eating Disorder as Owner Lucerne Biosciences Provides Patent Board Profile of itself and its High 40-75% Misrepresentation Rate
11. A Breakthrough Discovery on Treating Resistant Biofilm Infections Was Presented January 12 at Medtech Showcase in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... ... health supplement developed by a neurosurgeon, has received a big bump in ... Daily Brain Booster is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... board-certified veterinary oncologist, has agreed to serve as strategic adviser to the ... Tripp is founder of the Bridge Animal Referral Center (BARC) in Edmonds, ...
(Date:9/19/2017)... , ... September 19, 2017 , ... First Choice ... States, named Dr. Howard Ng, as the new Medical Director of its Pflugerville- FM ... new facility Medical Director of our Pflugerville- FM 685 location,” said Dr. Stephen Van ...
(Date:9/19/2017)... ... , ... Ron Norman, CEO of Team Decades, http://www.teamdecades.com , stressed to ... than generic impression in the job market if one is looking for career expansion. ... that the first impression they give off is not a good one," says Norman, ...
(Date:9/19/2017)... ... 19, 2017 , ... When it comes to household safety, there are few ... how to keep babies and toddlers safe, and there's no better time for companies ... Time to Check Labels, Brands that sell all kinds of common consumer products should ...
Breaking Medicine News(10 mins):